167 related articles for article (PubMed ID: 30061130)
1. Fatal case of macrophage activation syndrome (MAS) in a patient with dermatomyositis and cytomegalovirus (CMV) viraemia.
Lange AV; Kazi S; Chen W; Barnes A
BMJ Case Rep; 2018 Jul; 2018():. PubMed ID: 30061130
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus infection complicating immunosuppressive therapy for dermatomyositis.
Hashimoto A; Okuyama R; Watanabe H; Tagami H; Aiba S
Acta Derm Venereol; 2006; 86(6):535-7. PubMed ID: 17106602
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P
Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426
[TBL] [Abstract][Full Text] [Related]
4. [Disease by CMV resistant to Ganciclovir. Should plasma valganciclovir levels be monitored in high risk patients?].
Sola E; Vega E; Gutiérrez C; López V; Cabello M; Burgos D; González Molina M; Siles J
Nefrologia; 2009; 29(2):180-1. PubMed ID: 19396331
[No Abstract] [Full Text] [Related]
5. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients.
Asberg A; Humar A; Jardine AG; Rollag H; Pescovitz MD; Mouas H; Bignamini A; Töz H; Dittmer I; Montejo M; Hartmann A;
Am J Transplant; 2009 May; 9(5):1205-13. PubMed ID: 19422345
[TBL] [Abstract][Full Text] [Related]
6. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
[TBL] [Abstract][Full Text] [Related]
7. [Clinical analysis of 5 cases of dermatomyositis complicated with macrophage activation syndrome].
Xing XY; Zhang JX; Zhu FY; Wang YF; Zhou XY; Li YH
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1214-1218. PubMed ID: 36533358
[TBL] [Abstract][Full Text] [Related]
8. Progressive, refractory macrophage activation syndrome as the initial presentation of anti-MDA5 antibody positive juvenile dermatomyositis: a case report and literature review.
Stewart JA; Price T; Moser S; Mullikin D; Bryan A
Pediatr Rheumatol Online J; 2022 Feb; 20(1):16. PubMed ID: 35193600
[TBL] [Abstract][Full Text] [Related]
9. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
10. CMV-induced neonatal thrombocytopenia: a case report and review of the literature.
Aslam M; Anderson JL; Guglietti D; Cardwell D
Am J Perinatol; 2007 Aug; 24(7):429-34. PubMed ID: 17597443
[TBL] [Abstract][Full Text] [Related]
11. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.
Humar A; Kumar D; Preiksaitis J; Boivin G; Siegal D; Fenton J; Jackson K; Nia S; Lien D
Am J Transplant; 2005 Jun; 5(6):1462-8. PubMed ID: 15888055
[TBL] [Abstract][Full Text] [Related]
12. Small bowel transplantation complicated by cytomegalovirus tissue invasive disease without viremia.
Avsar Y; Cicinnati VR; Kabar I; Wolters H; Anthoni C; Schmidt HH; Beckebaum S
J Clin Virol; 2014 Jun; 60(2):177-80. PubMed ID: 24703746
[TBL] [Abstract][Full Text] [Related]
13. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
Perrottet N; Manuel O; Lamoth F; Venetz JP; Sahli R; Decosterd LA; Buclin T; Pascual M; Meylan P
BMC Infect Dis; 2010 Jan; 10():2. PubMed ID: 20053269
[TBL] [Abstract][Full Text] [Related]
14. Valganciclovir versus IV ganciclovir for therapy of cytomegalovirus viremia: has victory been achieved?
Avery RK
Am J Transplant; 2007 Sep; 7(9):2062-3. PubMed ID: 17697259
[No Abstract] [Full Text] [Related]
15. Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients.
Luan FL; Chopra P; Park J; Norman S; Cibrik D; Ojo A
Transplant Proc; 2006 Dec; 38(10):3673-5. PubMed ID: 17175363
[TBL] [Abstract][Full Text] [Related]
16. [Valganciclovir for treatment of cytomegalovirus viremia in patients following allogeneic hematopoietic stem cell transplantation].
Wang Y; Huang XJ; Xu LP; Liu DH; Chen YH; Han W; Wang J; Liu KY
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(46):3265-7. PubMed ID: 19159551
[TBL] [Abstract][Full Text] [Related]
17. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
18. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
[TBL] [Abstract][Full Text] [Related]
19. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy.
Kalil AC; Freifeld AG; Lyden ER; Stoner JA
PLoS One; 2009; 4(5):e5512. PubMed ID: 19436751
[TBL] [Abstract][Full Text] [Related]
20. High incidence of cytomegalovirus disease in D+/R- heart transplant recipients shortly after completion of 3 months of valganciclovir prophylaxis.
Gupta S; Mitchell JD; Markham DW; Mammen PP; Patel PC; Kaiser P; Ring WS; DiMaio JM; Drazner MH
J Heart Lung Transplant; 2008 May; 27(5):536-9. PubMed ID: 18442720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
